RU2262352C2 - Применение агонистов рецепторов b-типа гамма-аминомасляной кислоты и их фармацевтически приемлемых производных при лечении никотиновой зависимости - Google Patents
Применение агонистов рецепторов b-типа гамма-аминомасляной кислоты и их фармацевтически приемлемых производных при лечении никотиновой зависимости Download PDFInfo
- Publication number
- RU2262352C2 RU2262352C2 RU2002105375/15A RU2002105375A RU2262352C2 RU 2262352 C2 RU2262352 C2 RU 2262352C2 RU 2002105375/15 A RU2002105375/15 A RU 2002105375/15A RU 2002105375 A RU2002105375 A RU 2002105375A RU 2262352 C2 RU2262352 C2 RU 2262352C2
- Authority
- RU
- Russia
- Prior art keywords
- nicotine
- gamma
- use according
- type
- aminobutyric acid
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 206010057852 Nicotine dependence Diseases 0.000 title claims abstract description 9
- 208000025569 Tobacco Use disease Diseases 0.000 title claims abstract description 9
- 239000000556 agonist Substances 0.000 title claims abstract description 7
- 102000005915 GABA Receptors Human genes 0.000 title abstract description 3
- 108010005551 GABA Receptors Proteins 0.000 title abstract description 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960000794 baclofen Drugs 0.000 claims abstract description 14
- 230000000391 smoking effect Effects 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- MQIWYGZSHIXQIU-UHFFFAOYSA-O 3-phosphopropylazanium Chemical compound NCCC[P+](O)=O MQIWYGZSHIXQIU-UHFFFAOYSA-O 0.000 claims abstract description 4
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- NHVRIDDXGZPJTJ-UHFFFAOYSA-N skf-97,541 Chemical compound CP(O)(=O)CCCN NHVRIDDXGZPJTJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000002170 ethers Chemical class 0.000 claims abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 39
- 229960002715 nicotine Drugs 0.000 claims description 38
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 36
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 20
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 10
- 239000000018 receptor agonist Substances 0.000 claims description 7
- 229940044601 receptor agonist Drugs 0.000 claims description 7
- 235000019788 craving Nutrition 0.000 claims description 5
- -1 esters ethers Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000013271 transdermal drug delivery Methods 0.000 claims description 3
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000007939 sustained release tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 5
- 206010012335 Dependence Diseases 0.000 abstract description 3
- 230000006399 behavior Effects 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000779 smoke Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 241000208125 Nicotiana Species 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 235000019504 cigarettes Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- QIIVUOWTHWIXFO-UHFFFAOYSA-N cgp-35348 Chemical compound CCOC(OCC)P(O)(=O)CCCN QIIVUOWTHWIXFO-UHFFFAOYSA-N 0.000 description 3
- 238000002485 combustion reaction Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 229930182840 (S)-nicotine Natural products 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000018405 transmission of nerve impulse Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical class OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000017934 GABA-B receptor Human genes 0.000 description 1
- 108060003377 GABA-B receptor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229930013610 lobeline Natural products 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
- 229960002525 mecamylamine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITM199A001715 | 1999-07-30 | ||
| IT1999MI001715A IT1313585B1 (it) | 1999-07-30 | 1999-07-30 | Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002105375A RU2002105375A (ru) | 2003-11-10 |
| RU2262352C2 true RU2262352C2 (ru) | 2005-10-20 |
Family
ID=11383467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002105375/15A RU2262352C2 (ru) | 1999-07-30 | 2000-06-30 | Применение агонистов рецепторов b-типа гамма-аминомасляной кислоты и их фармацевтически приемлемых производных при лечении никотиновой зависимости |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1202727B1 (enExample) |
| CN (1) | CN1176650C (enExample) |
| AT (1) | ATE285763T1 (enExample) |
| AU (1) | AU6153400A (enExample) |
| CA (1) | CA2379752C (enExample) |
| DE (1) | DE60017147T2 (enExample) |
| DK (1) | DK1202727T3 (enExample) |
| ES (1) | ES2235913T3 (enExample) |
| HK (1) | HK1046849B (enExample) |
| IL (2) | IL147876A0 (enExample) |
| IT (1) | IT1313585B1 (enExample) |
| PL (1) | PL196334B1 (enExample) |
| PT (1) | PT1202727E (enExample) |
| RU (1) | RU2262352C2 (enExample) |
| SI (1) | SI1202727T1 (enExample) |
| WO (1) | WO2001008675A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011081558A1 (ru) * | 2009-08-21 | 2011-07-07 | Komissarov Jury Vladimirovich | Курительное устройство для отказа от табачного курения |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005019163A2 (en) * | 2003-08-20 | 2005-03-03 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| EP2354120A1 (en) | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| WO2006050471A2 (en) | 2004-11-03 | 2006-05-11 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
| WO2006050472A2 (en) | 2004-11-03 | 2006-05-11 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids |
| US7585996B2 (en) | 2006-09-15 | 2009-09-08 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| JP4498407B2 (ja) | 2006-12-22 | 2010-07-07 | キヤノン株式会社 | プロセスカートリッジ、電子写真画像形成装置、及び、電子写真感光体ドラムユニット |
| JP5291123B2 (ja) | 2008-01-25 | 2013-09-18 | ゼノポート，インコーポレイティド | （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用 |
| WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| EP2250148B1 (en) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
| US7989641B2 (en) | 2008-08-07 | 2011-08-02 | Xenoport, Inc. | Methods of synthesizing N-hydroxysuccinimidyl carbonates |
| WO2010017504A1 (en) | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| JP2012519212A (ja) | 2009-03-03 | 2012-08-23 | ゼノポート，インコーポレイティド | Ｒ−バクロフェンプロドラッグの持効性放出経口投与形 |
| US8344028B2 (en) | 2009-04-17 | 2013-01-01 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as GABAB receptor ligands |
| US8580850B2 (en) | 2011-08-11 | 2013-11-12 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use |
| WO2019195813A1 (en) * | 2018-04-06 | 2019-10-10 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of substance use disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| RU2132203C1 (ru) * | 1998-09-03 | 1999-06-27 | Шакирзянов Галимзян Закирович | Способ лечения табачной зависимости и антитабачный комбинированный препарат |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
| US5073539A (en) * | 1990-01-22 | 1991-12-17 | Ciba-Geigy Corporation | Transdermal administration of zwitterionic drugs |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
-
1999
- 1999-07-30 IT IT1999MI001715A patent/IT1313585B1/it active
-
2000
- 2000-06-30 WO PCT/EP2000/006120 patent/WO2001008675A1/en not_active Ceased
- 2000-06-30 CN CNB00811031XA patent/CN1176650C/zh not_active Expired - Lifetime
- 2000-06-30 CA CA002379752A patent/CA2379752C/en not_active Expired - Fee Related
- 2000-06-30 PL PL353373A patent/PL196334B1/pl unknown
- 2000-06-30 DK DK00947901T patent/DK1202727T3/da active
- 2000-06-30 EP EP00947901A patent/EP1202727B1/en not_active Expired - Lifetime
- 2000-06-30 AT AT00947901T patent/ATE285763T1/de active
- 2000-06-30 IL IL14787600A patent/IL147876A0/xx active IP Right Grant
- 2000-06-30 ES ES00947901T patent/ES2235913T3/es not_active Expired - Lifetime
- 2000-06-30 PT PT00947901T patent/PT1202727E/pt unknown
- 2000-06-30 RU RU2002105375/15A patent/RU2262352C2/ru active
- 2000-06-30 SI SI200030632T patent/SI1202727T1/xx unknown
- 2000-06-30 HK HK02107911.9A patent/HK1046849B/en not_active IP Right Cessation
- 2000-06-30 DE DE60017147T patent/DE60017147T2/de not_active Expired - Lifetime
- 2000-06-30 AU AU61534/00A patent/AU6153400A/en not_active Abandoned
-
2002
- 2002-01-28 IL IL147876A patent/IL147876A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| RU2132203C1 (ru) * | 1998-09-03 | 1999-06-27 | Шакирзянов Галимзян Закирович | Способ лечения табачной зависимости и антитабачный комбинированный препарат |
Non-Patent Citations (1)
| Title |
|---|
| реферат из АБД Medline: Oset-Gasque MJ et al. GABAB receptors modulate catecholamine secretion in chromaffin cells by a mechanism involving cyclic AMP formation. Br J Pharmacol. 1993 Dec; 110 (4): 1586-92 реферат из АБД Medline: Kerr D.I.et al 3-amino-2-(4-chlorophenyl)-nitropropane is a new GABAB receptor agonist, more active peripherally. Eur J Pharmacol. 1993 May 19; 236 (2): 239-45. ГАРНИЦКАЯ A.C Аффективные расстройства в формировании и клинике табачной зависимости Автореферат дисс. на соискание ученой степени кандидата медицинских наук М 1999 (разослан 02.07.1999) с.1, 14-19 реферат из АБД Medline: Martellotta MC et al. Intravenous self-administration of gamma-hydroxybutyric acid in dmg-naive mice. Eur Newopsychopharmacol. 1998 Dec; 8 (4): 293-6. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011081558A1 (ru) * | 2009-08-21 | 2011-07-07 | Komissarov Jury Vladimirovich | Курительное устройство для отказа от табачного курения |
Also Published As
| Publication number | Publication date |
|---|---|
| SI1202727T1 (enExample) | 2005-08-31 |
| CA2379752C (en) | 2008-05-27 |
| DE60017147T2 (de) | 2006-01-12 |
| CN1377265A (zh) | 2002-10-30 |
| PT1202727E (pt) | 2005-05-31 |
| DK1202727T3 (da) | 2005-05-09 |
| EP1202727A1 (en) | 2002-05-08 |
| ATE285763T1 (de) | 2005-01-15 |
| ITMI991715A0 (it) | 1999-07-30 |
| HK1046849B (en) | 2005-07-15 |
| IL147876A0 (en) | 2002-08-14 |
| DE60017147D1 (de) | 2005-02-03 |
| CN1176650C (zh) | 2004-11-24 |
| HK1046849A1 (en) | 2003-01-30 |
| IT1313585B1 (it) | 2002-09-09 |
| EP1202727B1 (en) | 2004-12-29 |
| ITMI991715A1 (it) | 2001-01-30 |
| PL353373A1 (en) | 2003-11-17 |
| AU6153400A (en) | 2001-02-19 |
| WO2001008675A1 (en) | 2001-02-08 |
| CA2379752A1 (en) | 2001-02-08 |
| IL147876A (en) | 2007-06-17 |
| PL196334B1 (pl) | 2007-12-31 |
| ES2235913T3 (es) | 2005-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2262352C2 (ru) | Применение агонистов рецепторов b-типа гамма-аминомасляной кислоты и их фармацевтически приемлемых производных при лечении никотиновой зависимости | |
| US6893654B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
| Sutherland et al. | Naltrexone, smoking behaviour and cigarette withdrawal | |
| US5026697A (en) | Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome | |
| JPH11505547A (ja) | ナルトレキソン及び関連化合物を用いる禁煙処置 | |
| JP2002522383A (ja) | 嗜癖又は嗜癖関連行動の治療 | |
| JP2002532393A (ja) | エキソ−ｒ−メカミラミン製剤および治療におけるその使用 | |
| Slater et al. | Inhibition of REM sleep by fluoxetine, a specific inhibitor of serotonin uptake | |
| WO1995007690A1 (en) | Composition and method for treating nicotine craving in smoking cessation | |
| RU2445971C2 (ru) | Водный экстракт листьев табака и его применение при лечении зависимости | |
| US6548510B1 (en) | Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence | |
| WO2006018538A1 (fr) | Medicament destine au traitement des desordres du systeme nerveux central | |
| Prignot | Pharmacological approach to smoking cessation | |
| Willette et al. | Acute and chronic interactive treatments of serotonin 5HT2C and dopamine D1 receptor systems for decreasing nicotine self-administration in female rats | |
| US20020168403A1 (en) | Compositions and therapy for substance addiction | |
| Oosterlinck et al. | Preliminary clinical experience with meptazinol, a new analgesic | |
| Clarke | Recent advances in understanding the actions of nicotine in the central nervous system | |
| RU2146942C1 (ru) | Способ лечения табакокурения | |
| EA012460B1 (ru) | Лекарство и способ для снижения потребления алкоголя и/или табака | |
| Golding et al. | Short-term effects of cigarette smoking | |
| JP2000515548A (ja) | ニコチン禁断症状を処置する方法 | |
| Chapman | Electrophysiological studies on the pharmacology of the processing of inflammatory nociception in the rat | |
| Sanberg et al. | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders | |
| CA2037353A1 (en) | Method of self-administering a dopamine 2 receptor agonist | |
| EA004718B1 (ru) | Способ сокращения или прекращения курения |